The risk for JC viral reactivation due to long-term use of Tysabri is much higher than for becoming newly infected. Therefore, the tests are aiming to screen for the presence of the virus itself or for signs of its reactivation. I haven't seen any data on IgM/acute phase, but perhaps we'll see them in the future as this is being studied recently just like the reactivation issue:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.